Trial Profile
A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9350-boosted Atazanavir (ATV/GS-9350) Compared to Ritonavir-boosted Atazanavir (ATV/r) in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat (Primary) ; Atazanavir; Emtricitabine/tenofovir disoproxil fumarate; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 27 Oct 2014 Planned End Date changed from 1 Jul 2012 to 1 Jan 2015, according to the the ClinicalTrials.gov record.
- 15 Sep 2010 Results were presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 19 Feb 2010 Status changed from recruiting to active, no longer recruiting.